Loading clinical trials...

A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer

Factors That Regulate Components of a Nutritional Supplement to Support Skeletal Muscle in Cancer Patients

NCT02745197•University of Alberta

View on ClinicalTrials.gov

Summary

This study evaluates a nutritional supplement in the treatment of pancreatic cancer in adults. Half of the participants will receive the nutritional supplement, while the other half will receive a placebo.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer scheduled for resection of the tumor.
•Patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer, subsequently found to have biliary or ampullary cancer upon full pathological review, scheduled for resection of the tumor.
•Patients with a CT image, which includes scans of the 3rd lumbar region, taken within 45 days before tumor resection surgery.
•Ability to maintain oral intake.
•Ability to give written, informed consent.

Exclusion Criteria

•Patients found to have a diagnosis other than pancreatic, biliary, or ampullary cancer upon full pathological review.
•Patients with a benign tumor.
•Patients taking drugs that modify muscle metabolism.
•Patients with uncontrolled jaundice.
•A compliance rate of \<80%, excluding compliance during recovery from tumor resection surgery while in the hospital.
•Patients currently taking the nutritional supplement being investigated in this study.
•Patients in the placebo group who have plasma levels of the nutritional supplement components within the range of the nutritional supplement group at study time points when plasma levels of the nutritional supplement components are significantly higher in the nutritional supplement group versus the placebo group.
•Inadequate specimens.
•Known allergy to gelatin or glycerin.

Key Dates

Start Date

May 1, 2017

Primary Completion Date

October 1, 2018

Completion Date

October 1, 2018

Last Updated

September 19, 2024

Conditions

Pancreatic Cancer

Interventions

Nutritional Supplement

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients